ClinicalTrials.gg
RecruitingNCT06656494Updated Aug 18, 2026

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

A Phase 1 interventional study of ICP-248 and Azacitidine in Acute Myelogenous Leukemia and Myelodysplastic Syndromes (MDS), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
266
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
36th of 433
266 · median 50
Started
2024
with 67 others
Phase 1
121 of 473
69 open now
Primary completion
2027-06
later than 171 of 288 live
Registered
340th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 36th largest by planned enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 121 in phase 1, reaches primary completion later than 171 of the 288 other live ones, and was the 340th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndromes (MDS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible subjects must meet all of the following criteria:

  1. Subject must have confirmation of diagnosis of AML (except for acute promyelocytic leukemia [APL]) or MDS per 2016 World Health Organization (WHO) criteria.
  2. For AML (except for APL) cohort:

    1. Previously treated AML subjects
    2. Treatment-naïve AML subjects should be: ≥60 years of age OR ≥18 years and \<60 years will be eligible if the subject has at least one of the following co-morbidities, which make the subject unfit for intensive chemotherapy
  3. For MDS cohort: Adult TN MDS and R/R MDS: revised International Prognostic Scoring System (IPSS-R) score > 3 and bone marrow blasts ≥ 5%.
  4. Subject must have a projected of at least 12 weeks.
  5. Subject must have adequate renal function as demonstrated by a ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft-Gault formula.
  6. Subject must have adequate liver function

Exclusion criteria

Exclusion Criteria:

  1. R/R AML or R/R MDS with no response or intolerance to post azacitidine or BCL-2i.
  2. Subject has acute promyelocytic leukemia (French-American-British Class M3 AML) .
  3. Subject has known central nervous system (CNS) leukemia.
  4. Suggest patients with active or C virus infection
  5. History of immunodeficiency, including a positive (HIV) antibody test.
  6. Subjects have another active within the past 2 years before study entry, except for curatively treated.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
266 participants (estimated)

Study arms

  • Experimental
    ICP-248 in combination with azacitidine

    Drug: ICP-248 · Drug: Azacitidine

Interventions

  • Eligible patients will receive ICP-248 orally as per the protocol,once daily for every 28 days as one treatment cycle

  • Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol,once daily on days 1-7 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Incidence, type, and severity of dose-limiting toxicity (DLT).

    Time frame: 2.5 years

  2. Recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD).

    Time frame: 2.5 years

  3. The incidence, nature, and severity of adverse events (AEs) as assessed per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) criteria.

    Time frame: 2.5 years

  4. AML cohort:Composite complete remission rate by Investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  5. AML cohort:Composite complete remission rate by completion of cycle 2 by Investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  6. MDS cohort:mOR rate, including CR, mCR, and PR, assessed by Investigator at any time point during the study per revised IWG 2006 MDS Criteria.

    Time frame: 2.5 years

Secondary outcomes

  1. AML cohort:Composite complete remission rate: The proportion of subjects with complete remission (CR) and CR with incomplete hematologic recovery (CRi) by Investigator per European Leukemia Net (ELN) 2017 criteria.

    Time frame: 2.5 years

  2. AML cohort:Composite complete remission rate by completion of cycle 2 by Investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  3. The incidence, nature, and severity of adverse events (AEs) as assessed per NCI-CTCAE v5.0 criteria.

    Time frame: 2.5 years

  4. Maximum concentration (Cmax)of ICP-248.

    Time frame: 2.5 years

  5. Area under the curve (AUC) of ICP-248.

    Time frame: 2.5 years

  6. Time of maximum observed plasma(Tmax)of ICP-248.

    Time frame: 2.5 years

  7. Trough concentration(Ctrough) of ICP-248.

    Time frame: 2.5 years

  8. Apparent clearance (CL/F) of ICP-248.

    Time frame: 2.5 years

  9. AML cohort:Partial Response (PR) by investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  10. AML cohort:Overall survival (OS) by investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  11. AML cohort:Duration of Response (DOR) by investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  12. AML cohort:Event-free Survival (EFS) by investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  13. AML cohort:Relapse-free Survival (RFS) by investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  14. AML cohort:Morphologic leukemia-free state (MLFS) by investigator per ELN 2017 criteria.

    Time frame: 2.5 years

  15. MDS cohort:Modified overall response (mOR) rate, including CR, marrow complete response (mCR), and PR, assessed by Investigator at any time point during the study per revised International Working Group (IWG) 2006 MDS Criteria

    Time frame: 2.5 years

  16. MDS cohort:Complete remission(CR) rate by Investigator per revised IWG 2006 MDS Criteria

    Time frame: 2.5 years

  17. MDS cohort:Event-free survival (EFS) by Investigator per revised IWG 2006 MDS Criteria

    Time frame: 2.5 years

  18. MDS cohort:Duration of modified overall response (DmOR) by Investigator per revised IWG 2006 MDS Criteria

    Time frame: 2.5 years

  19. MDS cohort:Overall survival(OS) by Investigator per revised IWG 2006 MDS Criteria

    Time frame: 2.5 years

  20. MDS cohort:Marrow complete response (mCR) rate by Investigator per revised IWG 2006 MDS Criteria

    Time frame: 2.5 years

07

Study locations

22 of 22 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 30 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 24, 2024
StartActual
Dec 18, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jan 2028
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06656494
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Dec 18, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 18, 2026

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesutoclax

Start the discussion